<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00842920</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2008-002226-11</org_study_id>
    <secondary_id>BMBF grant, 01KG0822</secondary_id>
    <nct_id>NCT00842920</nct_id>
  </id_info>
  <brief_title>Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients</brief_title>
  <acronym>SIMaMCI</acronym>
  <official_title>Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Probands with MCI are at high risk to develop Alzheimer´s dementia (AD). Simvastatin may
      lower the production of Amyloid, a hallmark of AD in the brain. The primary hypothesis of the
      study is that 60 mg Simvastatin significantly reduces the Clinical Dementia Rating -Sum of
      boxes (CDR-SOB) in individuals with MCI as compared to MCI receiving placebo or 20 mg
      Simvastatin
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a national multicenter, double-blind, randomized placebo-controlled trial allowing
      for a minimum follow-up time of 24 months in conversion-free patients. Randomization will be
      stratified by prior use of statins.

      The two strata are:

        1. &quot;no-statins&quot;: patients without treatment with a statins and no indication for treatment
           (according to the guidelines of the German Society of Cardiology for the primary
           prevention of cardiovascular disease); patients will be randomly assigned to one of 2
           treatment (1) Simvastatin (60 mg) one tablet/day (2) Placebo one tablet/day.

        2. &quot;low-statins&quot;: patients treated with low doses of Statins; patients will be randomly
           assigned to one of 2 treatment (1) Simvastatin (60 mg) one tablet/day (2) 20 mg
           Simvastatin one tablet/day.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2008</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CDR-SOB at 24 months of treatment</measure>
    <time_frame>24 month</time_frame>
    <description>Clinical dementia rating - sum of boxes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) score</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Free and Cued Selective Reminding Test (FCSRT) score</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of conversion-free interval, starting at the time of randomization, with conversion being defined as an increase of the CDR score beyond 0.5</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in CDR-SOB at Long-Term Follow-Up</measure>
    <time_frame>2-11 years</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo or 20 mg Simvastatin (stratified by prior use of statins)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 60 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simvastatin 20 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 60 mg</intervention_name>
    <description>60 mg once daily</description>
    <arm_group_label>Simvastatin 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one tablet once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 20 mg</intervention_name>
    <description>20 mg once daily</description>
    <arm_group_label>Simvastatin 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Self and informant report of gradually increasing memory impairment for at least six
             months.

          2. Objective memory impairment

          3. Intact basic activities of daily living

          4. Preserved general cognitive function, not demented

          5. Absence of a detectable cause of memory disorder

          6. Age 55 to 90.

          7. Females without childbearing potential

          8. A total cholesterol ≥90 mg/dl

          9. LDL-cholesterol ≥ 160 mg/dl and ≤ 3 risk factors or ≥ 190 mg/dl and ≤ 2 risk factors
             including age

         10. Informed consent (according german medicinal products act, AMG §40 (1) 3b)

         11. No participation in other clinical trials 2 months before and after participation in
             this study

         12. Probands should only recruited for the clinical trial, when they are able to perform
             the informed consent; due to worsening of &quot;memory function&quot; in the course of the
             clinical trial, probands should not longer participate the clinical trial, when they
             is evidence, that participants were not longer able to give full informed consent.

        Exclusion Criteria:

          1. Hypersensitivity against Simvastatin, active liver disease or lasting increase of
             serum transaminases for unclear reason

          2. Unstable medical, neurological or psychiatric disease

          3. Lack of a spouse or a close relative

          4. Use of a registered anti-dementia drug or a nootropic

          5. Chronic use of anti-inflammatory drugs

          6. History of stroke or myocardial infarction

          7. LDL-cholesterol 130-160 mg/dl and &gt; 3 risk factors or 160-190 mg/dl and &gt; 2 risk
             factors including age.

          8. LDL-cholesterol &gt;190 mg/dl

          9. Comedication with Diltiazem, Verapamil, Amiodarone, Itraconazole, Ketoconazole,
             Erythromycin, Clarithromycin, Telithromycin, Ciclosporin, Gemfibrozil, Nefazodone,
             HIV-protease inhibitors, Benzodiazepines, Tricyclic antipsychotics or other
             anticholinergic drugs

         10. Comedication of other statins in high doses; low doses equivalent to 20 mg Simvastatin
             are allowed if taken for max. 2 years before randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabella Heuser, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité-CBF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lutz Frölich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIMH Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, Charité-CBF</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, University Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, University Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, Johann Wolfgang Goethe-University</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Geriatrics and Gerontology, University Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, Medical University Goettingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department for Psychiatry, Psychotherapy and Psychosomatic; Martin-Luther-University Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <zip>06112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Gerontopsychiatry, Central Institut of Mental Health, University Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <zip>68072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, LMU I</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Stroke and Dementia Research, LMU</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy, University Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 11, 2009</study_first_submitted>
  <study_first_submitted_qc>February 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2009</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Isabella Heuser</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>amnestic MCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

